Organogenesis Holdings Inc. (ORGO) Form 10-Q — Aug 6, 2026
Organogenesis posted Q2 2026 total revenue of $43.8 million, down 57% from $101.0 million a year earlier, as 2026 CMS Medicare reimbursement changes for skin substitutes drove its Advanced Wound Care franchise down to $36.1 million from $92.7 million. Net loss widened roughly tenfold to $96.3 million, or $0.77 per share, from $9.4 million, including a $45.4 million income tax charge after the company established a full valuation allowance on its deferred tax assets — a signal management does not expect near-term taxable income.
Key figures
- Revenue
- 43755000
- Revenue Yoy
- -56.7% (Q2 2026 vs Q2 2025)
- Total Assets
- 406446000
- Cash Position
- 46097000
- Shares Outstanding
- 128674548
- Revolving facility
- $75.0M (expired August 6, 2026; no borrowings outstanding)
- Term loan facility
- $75.0M (prepaid November 2024)
- Cash at dec 31 2025
- 93679000
- H1 2026 total revenue
- 80983000
- Q2 income tax expense
- 45387000
- Q2 net product revenue
- 42805000
- Q2 advanced wound care revenue
- 36146000
- Cms skin substitute payment rate
- $127.14 per square centimeter (2026 PFS/OPPS final rules)
- Q2 surgical sports medicine revenue
- 6659000
- Direct sales reps after restructuring
- 148
- Preferred stock liquidation preference
- 147963000
Price after filing
Close on the filing date to close N calendar days later (from $2.37). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.